Valuation: ARRD RESE

Market Cap 939.06Cr 818.86Cr 773.19Cr 702.12Cr 1.32TCr 90TCr 1.32TCr 9.26TCr 3.57TCr 46TCr 3.53TCr 3.45TCr 1,47400Cr P/E 2026 *
-18.3x
P/E 2027 * -14.4x
Enterprise Value 855.82Cr 746.28Cr 704.66Cr 639.88Cr 1.2TCr 82TCr 1.2TCr 8.44TCr 3.26TCr 42TCr 3.21TCr 3.14TCr 1,34300Cr EV / Sales 2026 *
18.6x
EV / Sales 2027 * 25.6x
Free-Float
94.56%
Yield 2026 *
-
Yield 2027 * -
16/09 Arrowhead Pharmaceuticals, Inc. Presents at H.C. Wainwright 28th Annual Global Investment Conference, Sep-16-2026 09:00 AM
15/09 Arrowhead Pharmaceuticals, Inc. Presents at Morgan Stanley 24th Annual Global Healthcare Conference, Sep-15-2026 11:30 AM
15/09 Arrowhead Pharmaceuticals Announces Interim Topline Clinical Data for Aro-Dimer-Pa Phase 1/2A Clinical Trial CI
10/09 Arrowhead Pharmaceuticals, Inc. Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference, Sep-10-2026 10:55 AM
08/09 Citigroup Initiates Arrowhead Pharmaceuticals at Buy With $108 Price Target MT
31/08 Arrowhead Pharmaceuticals' sHTG Therapy Could Get FDA Approval by Q2 2027, RBC Says MT
31/08 Arrowhead Pharmaceuticals, Inc. - Special Call
31/08 Arrowhead Pharmaceuticals' Plozasiran Meets Endpoints in Studies of Patients With Severe Hypertriglyceridemia MT
30/08 Arrowhead Pharmaceuticals Presents Phase 3 SHASTA-3 And SHASTA-4 Data Demonstrating Plozasiran Reduced Acute Pancreatitis Events In Patients With Severe Hypertriglyceridemia CI
24/08 Arrowhead Pharmaceuticals Presents New Clinical Data and Product Updates At European Society of Cardiology Congress CI
21/08 Arrowhead Pharmaceuticals Insider Sold Shares Worth $1,012,680, According to a Recent SEC Filing MT
17/08 Arrowhead Pharmaceuticals' Redemplo Now Available in Germany for FCS Patients MT
17/08 Arrowhead Pharmaceuticals Lists REDEMPLO In Lauer-Taxe Database As Adjunct To Diet To Reduce Triglyceride Levels In Adult Patients With Familial Chylomicronaemia Syndrome In Germany CI
Manager TitleAgeSince
Chief Executive Officer 56 01/12/2007
Director of Finance/CFO - 13/05/2025
Chief Tech/Sci/R&D Officer - 01/08/2022
Director TitleAgeSince
Chairman 56 -
Director/Board Member 66 19/08/2010
Director/Board Member 66 19/12/2011
Change 5-day change 1-year change 3-year change Capi.($)
-0.31%+5.79%+47.13%+99.00% 7.09TCr
+0.39%+2.06%+39.38%+78.27% 6.25TCr
+0.50%+7.13%+33.27%+16.01% 2.63TCr
-3.21%-7.27%-17.10%+356.10% 2.62TCr
-2.64%-0.69%-0.17%-13.01% 2.41TCr
+0.71%+8.03%+25.03%-12.74% 2.07TCr
+2.12%-5.86%+161.58%+329.34% 1.54TCr
-0.22%+3.99%+45.54%+172.46% 1.45TCr
+0.73%+1.71%-5.51%+849.47% 1.42TCr
Average -0.21%+1.74%+36.57%+208.32% 3.05TCr
Weighted average by Cap. -0.28%+1.49%+35.68%+148.22%

Financials

2026 *2027 *
Net sales 46Cr 40Cr 38Cr 34Cr 65Cr 4.43TCr 65Cr 454.87Cr 175.53Cr 2.25TCr 173.25Cr 169.4Cr 7.24TCr 34Cr 30Cr 28Cr 25Cr 48Cr 3.26TCr 48Cr 335.28Cr 129.38Cr 1.66TCr 127.7Cr 124.86Cr 5.34TCr
Net income -52Cr -45Cr -43Cr -39Cr -73Cr -4.98TCr -73Cr -511.37Cr -197.34Cr -2.53TCr -194.77Cr -190.45Cr -8.14TCr -65Cr -57Cr -53Cr -49Cr -91Cr -6.23TCr -91Cr -640.61Cr -247.21Cr -3.17TCr -243.99Cr -238.58Cr -10TCr
Net Debt -83Cr -73Cr -69Cr -62Cr -116.6Cr -7.99TCr -117.09Cr -820.93Cr -316.79Cr -4.06TCr -312.67Cr -305.73Cr -13TCr -68Cr -60Cr -56Cr -51Cr -96Cr -6.55TCr -96Cr -673.41Cr -259.87Cr -3.33TCr -256.49Cr -250.79Cr -11TCr
Logo ARRD RESE
Arrowhead Pharmaceuticals, Inc. develops medicines that treat intractable diseases by silencing the genes that cause them. The Company's therapies, using a broad portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, trigger the RNA interference (RNAi) mechanism to induce rapid, deep and durable knockdown of target genes. Its Targeted RNAi Molecule (TRiMTM) platform utilizes ligand-mediated delivery and is designed to enable tissue-specific targeting while being structurally simple. It is focused on various therapeutic areas, such as cardiometabolic, pulmonary, liver, neuromuscular and others. It has over 18 discovered drug candidates in clinical trials ranging from early stage (Phase I) to late stage (Phase III). The Company's pipeline products include plozasiran, zodasiran, olpasiran, ARO-RAGE, SRP-1002, GSK4532990, fazirsiran, daplusiran/tomligisiran, ARO-CFB, ARO-INHBE, ARO-C3, ARO-PNPLA3, SRP-1001 (ARO-DUX4), SRP-1003 (ARO-DM1), SRP-1004 (ARO-ATXN2), and others.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!